GLP-3 Weight Loss Drugs: What Triple Agonists Mean

When people search for “GLP-3,” they are usually referring to a new class of triple-agonist weight-loss medications.

There is no human hormone called GLP-3.

The term is internet shorthand for drugs designed to activate three metabolic receptors at the same time:

• GLP-1
• GIP
• Glucagon

The most advanced example in this category is retatrutide, which is currently investigational and not FDA-approved.

Quick Overview

• “GLP-3” is not a real hormone.
• It typically refers to triple-agonist drugs targeting GLP-1, GIP, and glucagon receptors.
• Retatrutide is the leading triple-agonist candidate in development.
• In phase 2 clinical trials, the highest dose of retatrutide produced about 24 percent average weight loss at 48 weeks.
• Retatrutide is still in clinical trials and not FDA-approved.

GLP-3 vs GLP-1: What Is the Difference?

GLP-1 medications target one main receptor involved in appetite control, stomach emptying, and glucose regulation. Triple-agonist medications target three pathways at once: GLP-1, GIP, and glucagon. That is why people online often call them “GLP-3,” even though GLP-3 is not an official hormone or drug class.

Category	GLP-1 Medications	Triple-Agonist Drugs
Common examples	Semaglutide-based medications	Retatrutide, currently investigational
Receptors targeted	GLP-1	GLP-1, GIP, and glucagon
Main goal	Appetite control and glucose support	Broader metabolic support through multiple pathways
Approval status	Some GLP-1 medications are FDA-approved for weight loss or diabetes	Retatrutide is not FDA-approved and remains under study
Safety note	Requires medical screening and monitoring	Requires clinical oversight and should not be purchased from unregulated sources

What Triple-Agonist Drugs Do

Triple-agonists are designed to stimulate three metabolic pathways simultaneously.

GLP-1 Receptor

• Reduces appetite
• Slows stomach emptying
• Improves post-meal glucose control

This pathway is already used in approved medications such as semaglutide.

GIP Receptor

• Influences insulin signaling
• Works alongside GLP-1 to regulate appetite and metabolism

This pathway is part of tirzepatide’s mechanism.

Glucagon Receptor

• May increase energy expenditure
• Influences fat metabolism

Adding glucagon receptor activity is what distinguishes triple-agonists from dual-agonists.

The goal of combining all three is greater weight loss and broader metabolic effects.

What Research Shows So Far

In a phase 2 clinical trial in adults with obesity:

• The highest dose of retatrutide led to approximately 24 percent average weight loss at 48 weeks.
• Participants were still losing weight at the end of the study period.
• Cardiometabolic markers such as blood pressure and lipids improved.
• Many individuals with prediabetes returned to normal glucose levels.

These results are promising. However, they come from phase 2 trials. Larger phase 3 trials are ongoing.

Retatrutide remains investigational.

Side Effects Observed in Trials

The side effect pattern is similar to GLP-1-based medications.

Common Side Effects

• Nausea
• Vomiting
• Diarrhea
• Constipation

These symptoms were generally dose-related and more common during dose increases.

Heart Rate

Modest increases in resting heart rate were observed.

Gradual dose escalation was associated with better tolerability.

GLP-3 Safety: What Patients Should Know

Triple-agonist drugs are still being studied, so patients should avoid treating online “GLP-3” products as proven or approved weight-loss medications. Retatrutide remains investigational, and products sold online for human use outside proper medical channels may create serious safety risks.

Reported side effects in studies include nausea, vomiting, diarrhea, constipation, and changes in resting heart rate. These effects make medical screening important, especially for patients with heart concerns, blood sugar issues, gastrointestinal conditions, or a history of medication sensitivity.

Patients should also be careful with unapproved or compounded products marketed as weight-loss injections. The FDA has warned about unapproved GLP-1 products sold for weight loss and has raised concerns about products labeled “for research purposes” being marketed directly to consumers. Medical supervision matters because dosing, product quality, side effects, and eligibility all affect safety.

Comparison With Current Approved Medications

Here is a simplified overview based on published trial data.

GLP-1 Only (Example: Semaglutide 2.4 mg)

• Mechanism: GLP-1 receptor activation
• Reported average weight loss: Around 15 percent at 68 weeks
• FDA-approved

Dual GIP/GLP-1 (Example: Tirzepatide)

• Mechanism: GIP + GLP-1 receptor activation
• Reported average weight loss: Up to about 22 percent at 72 weeks
• FDA-approved

Triple GLP-1/GIP/Glucagon (Example: Retatrutide)

• Mechanism: GLP-1 + GIP + glucagon receptor activation
• Reported average weight loss: Up to about 24 percent at 48 weeks
• Investigational

These numbers come from separate trials and are not direct head-to-head comparisons.

Regulatory Status and Access

Retatrutide is:

• In phase 3 clinical trials
• Not FDA-approved
• Only available through clinical trials

Consumers should avoid products marketed online as retatrutide outside research settings. Counterfeit and unregulated products pose serious safety risks.

Body Composition During Weight Loss

Large weight loss from any method includes both:

• Fat mass
• Lean tissue

Research on GLP-1–based medications shows lean tissue can represent roughly 25–40 percent of total weight lost without resistance training and adequate protein intake.

This highlights the importance of:

• Strength training
• Adequate protein
• Medical monitoring

The number on the scale does not tell the whole story. Patients focused on fat loss while preserving lean tissue may also benefit from reviewing fat loss injection options and a supervised nutrition plan.

Bottom Line

“GLP-3” refers to triple-agonist medications like retatrutide that target GLP-1, GIP, and glucagon receptors.

Early clinical trials show substantial weight loss potential. However, retatrutide is not FDA-approved and remains investigational.

Weight-loss medications should always be considered within a comprehensive plan that includes:

• Nutrition
• Resistance training
• Medical supervision
• Monitoring of body composition

If you are exploring advanced weight-loss therapies, consult a qualified healthcare provider to determine what is appropriate for your health profile.

If you want a safer plan built around your health history, labs, and goals, explore our medical weight loss consultation options at Tucson Wellness MD.

Frequently Asked Questions

What does GLP-3 mean in weight loss?
GLP-3 is not a real human hormone. The term is commonly used online to describe triple-agonist medications that target GLP-1, GIP, and glucagon receptors at the same time. These drugs are designed to influence appetite, glucose control, and energy expenditure. The term is informal and does not represent an official medical classification.

Is GLP-3 a real hormone?
No, GLP-3 does not exist as a hormone in the human body. It is a shorthand term used to describe a combination of three metabolic pathways targeted by certain investigational drugs. This distinction is important because it helps prevent confusion with actual hormones like GLP-1. Understanding the terminology helps set realistic expectations.

What is retatrutide and how does it work?
Retatrutide is an investigational triple-agonist drug that activates GLP-1, GIP, and glucagon receptors. Each receptor plays a role in appetite control, insulin signaling, and energy use. By targeting all three, the drug aims to produce broader metabolic effects than current treatments. It is still undergoing clinical trials and is not yet approved.

How effective are triple-agonist weight-loss drugs?
Early research shows promising results, with significant average weight loss observed in clinical trials. Some participants achieved around 24 percent weight loss over several months. However, these findings come from controlled studies and are not guaranteed in real-world use. More research is needed to confirm long-term outcomes.